Why the Clinuvel (ASX:CUV) share price has rocketed 50% in a month

The Clinuvel Pharmaceuticals share price has had a fantastic 30 days.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price is having a great month on the ASX.

The company's stock was seemingly boosted significantly by its financial year 2021 earnings and has managed to hold onto its gains.

Right now, the Clinuvel share price is $41.05, having gained 50.7% since this time last month and 0.8% since its previous close.

Let's take a closer look at what Clinuvel reported within its financial year 2021 results.

Monadelphous share price rio tinto A small rocket take off from a laptop, indicating a share price surge

Image source: Getty Images

What's been driving Clinuvel on the ASX lately?

The Clinuvel share price has been performing exceptionally well since it released its annual results for financial year 2021.

Over the financial year just been, Clinuvel received a record $48.5 million of revenue and $24.7 million of profit after tax.

That represents respective increases of 43% and 63% on those of the previous financial year.

Clinuvel also announced a 2.5 cent dividend, in line with its dividend from the previous financial year. Though, Clinuvel's dividends have historically been unfranked.

Over the 12 months ended 30 June 2021, Clinvuel implemented a long-term strategy for the development and commercialisation of its novel drug technology.

It also outlined its plans to increase its operations in countries including the US, Israel, and those in Europe in its results.

On the day it released its financial year 2021 earnings, the Clinuvel share price gained just 3.1%. However, it gained another 38.3% over the following 6 sessions.

Clinuvel share price snapshot

The Clinuvel share price's recent 50% gain has added to its strong performance on the ASX.

Right now, Clinuvel's stock is 80% higher than it was at the start of this year. It is also trading for 74% more than it was this time last year.

At its current share price, the company has a market capitalisation of around $2 billion. It has approximately 49 million shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Group of scientists cheering in the lab after the company received good news.
Healthcare Shares

Mesoblast shares are up sharply. Is this biotech still undervalued?

Mesoblast faces big risks, but brokers see substantial upside if successful.

Read more »

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

Why is this ASX 300 healthcare stock up more than 17%?

Strong earnings have this company riding high.

Read more »

Two people comparing and analysing material.
Healthcare Shares

Could the CSL share price reach $200 in 2027?

It might sound ambitious after recent struggles, but the valuation required to get there is less demanding than you might…

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Mesoblast share price jumps on blockbuster news

It has been a good start to the week for this biotech company.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Australian Clinical Labs delivers profit growth and stronger margins in FY26

Australian Clinical Labs’ FY26 earnings reveal profit growth and margin improvements despite market headwinds.

Read more »

medical research laboratory assistant examines solutions in test tubes
Healthcare Shares

CSL shares are rallying. Could tomorrow's results pour fuel on the fire?

One strong month isn't enough. CSL needs earnings recovery to follow.

Read more »

A man with a perplexed expression on his face scratches his head.
Healthcare Shares

4DMedical shares are up 670% — but why have they halved?

Can the company turn its commercial momentum into another explosive share-price rebound?

Read more »

Businesswoman with a pleased smile reading on her laptop at a desk in the office with a look of satisfaction.
Healthcare Shares

Are CSL shares dirt cheap and a strong buy?

There is plenty for CSL to prove next week. The current valuation is why I am still interested.

Read more »